{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T10:08:43Z","timestamp":1785146923517,"version":"3.55.0"},"reference-count":166,"publisher":"MDPI AG","issue":"15","license":[{"start":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T00:00:00Z","timestamp":1785110400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Int. J. Mol. Sci.","IJMS"],"abstract":"<jats:p>Virus-based cancer therapy (virotherapy) is currently being researched as a novel form of immunotherapy and has already entered the clinical application phase. Among various types of virotherapy, oncolytic virotherapy involves infecting tumors with tumor-selective viruses, such as herpes simplex virus, adenoviruses, and vaccinia virus, and utilizing their replicative capacity to induce cell destruction within tumors. In addition, this therapy aims to enhance tumor immunity by changing the tumor microenvironment through viral infection. Genetic deletion in viruses is used to reduce their virulence and confer tumor selectivity, while the expression of foreign genes is utilized to enhance antitumor effects. Oncolytic viruses for head and neck cancer (HNC) are administered locally or systemically and are sometimes used as adjuvant therapy or in combination with immune checkpoint inhibitors. Another form of virotherapy involves non-replicating viruses, which are used to produce antitumor cytokines or as cancer vaccines expressing tumor antigens. Research on the efficacy of cancer vaccines in preventing postoperative recurrence is currently underway. A number of challenges have yet to be overcome for further advances in virotherapy, including the efficient delivery of viruses to tumor cells, avoiding viral inactivation in the bloodstream, ensuring efficient replication of the virus, and enhancing antitumor immunity. The development of effective strategies based on the findings of clinical studies will lead to improvements in virotherapy for HNC.<\/jats:p>","DOI":"10.3390\/ijms27156682","type":"journal-article","created":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T09:47:41Z","timestamp":1785145661000},"page":"6682","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Clinical Progress in Virotherapy: Application and Future Prospects in Head and Neck Cancer"],"prefix":"10.3390","volume":"27","author":[{"given":"Yoshiaki","family":"Yura","sequence":"first","affiliation":[{"name":"Department of Oral & Maxillofacial Oncology and Surgery, Graduate School of Dentistry, The University of Osaka, Suita 565-0871, Osaka, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masakazu","family":"Hamada","sequence":"additional","affiliation":[{"name":"Department of Oral & Maxillofacial Oncology and Surgery, Graduate School of Dentistry, The University of Osaka, Suita 565-0871, Osaka, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,7,27]]},"reference":[{"key":"ref_1","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J. Clin."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1001\/jama.2025.21733","article-title":"Head and Neck Cancer: A Review","volume":"335","author":"Dunn","year":"2026","journal-title":"JAMA"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1937","DOI":"10.1056\/NEJMoa032646","article-title":"Postoperative concurrent radiotherapy and chemotherapy for high-risk squamous-cell carcinoma of the head and neck","volume":"350","author":"Cooper","year":"2004","journal-title":"N. Engl. J. Med."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1856","DOI":"10.1056\/NEJMoa1602252","article-title":"Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck","volume":"375","author":"Ferris","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1016\/S0140-6736(19)32591-7","article-title":"Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): A randomised, open-label, phase 3 study","volume":"394","author":"Burtness","year":"2019","journal-title":"Lancet"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"107791","DOI":"10.1016\/j.oraloncology.2025.107791","article-title":"Subcutaneous amivantamab in recurrent\/metastatic head and neck squamous cell cancer after disease progression on checkpoint inhibitor and chemotherapy: Preliminary results from the phase 1b\/2 OrigAMI-4 study","volume":"171","author":"Harrington","year":"2025","journal-title":"Oral Oncol."},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Jove, M., Bra\u00f1a, I., Oliva, M., Hernando-Calvo, A., Erasun, C., Mato-Berciano, A., Maliandi, M.V., Torres-Manjon, S., Rojas, L.A., and Connelly, S. (Cin. Cancer Res., 2026). Phase I trial of intravenous VCN-01 oncolytic adenovirus and durvalumab in patients with head and neck metastatic squamous cell carcinoma refractory to immunotherapy, Cin. Cancer Res.","DOI":"10.1158\/1078-0432.CCR-26-0601"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"2389","DOI":"10.1080\/21645515.2020.1723363","article-title":"Recent advances of oncolytic virus in cancer therapy","volume":"16","author":"Mondal","year":"2020","journal-title":"Hum. Vaccines Immunother."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1038\/s41392-023-01407-6","article-title":"Oncolytic virotherapy: Basic principles, recent advances and future directions","volume":"8","author":"Lin","year":"2023","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Muthukutty, P., and Yoo, S.Y. (2023). Oncolytic Virus Engineering and Utilizations: Cancer Immunotherapy Perspective. Viruses, 15.","DOI":"10.3390\/v15081645"},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Enow, J.A., Sheikh, H.I., and Rahman, M.M. (2023). Tumor Tropism of DNA Viruses for Oncolytic Virotherapy. Viruses, 15.","DOI":"10.3390\/v15112262"},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Smestad, J., Rieth, J., Laux, D., and Milhem, M. (2025). The Evolution, Current Landscape, and Future Prospects of Oncolytic Virotherapy in Melanoma: Talimogene Laherparepvec and Beyond. Cells, 14.","DOI":"10.3390\/cells14201620"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1038\/cgt.2016.8","article-title":"Immunogenic cell death by oncolytic herpes simplex virus type 1 in squamous cell carcinoma cells","volume":"23","author":"Takasu","year":"2016","journal-title":"Cancer Gene Ther."},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Lovatt, C., and Parker, A.L. (2023). Oncolytic Viruses and Immune Checkpoint Inhibitors: The \u201cHot\u201d New Power Couple. Cancers, 15.","DOI":"10.20944\/preprints202307.1892.v1"},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Hamada, M., and Yura, Y. (2020). Efficient Delivery and Replication of Oncolytic Virus for Successful Treatment of Head and Neck Cancer. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21197073"},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Wang, Z., Sun, P., Li, Z., and Xiao, S. (2023). Clinical Advances and Future Directions of Oncolytic Virotherapy for Head and Neck Cancer. Cancers, 15.","DOI":"10.3390\/cancers15215291"},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Gupta, A., Chavan, S.R., Gadepalli, R., and Pareek, P. (2025). Oncolytic viruses in head and neck cancers: Clinical applications and therapeutic potential. Front. Microbiol., 16.","DOI":"10.3389\/fmicb.2025.1641267"},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Volovat, S.R., Scripcariu, D.V., Vasilache, I.A., Stolniceanu, C.R., Volovat, C., Augustin, I.G., Volovat, C.C., Ostafe, M.R., Andreea-Voichi\u021ba, S.G., and Bejusca-Vieriu, T. (2024). Oncolytic Virotherapy: A New Paradigm in Cancer Immunotherapy. Int. J. Mol. Sci., 25.","DOI":"10.3390\/ijms25021180"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1007\/s10238-025-01691-2","article-title":"Oncolytic virotherapy and tumor microenvironment modulation","volume":"25","author":"Bautista","year":"2025","journal-title":"Clin. Exp. Med."},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Spirito, F., Nocini, R., Mori, G., Albanese, M., Georgakopoulou, E.A., Sivaramakrishnan, G., Khalil, B., \u0160piljak, B., Surya, V., and Mishra, D. (2024). The Potential of Oncolytic Virotherapy in the Treatment of Head and Neck Cancer: A Comprehensive Review. Int. J. Mol. Sci., 25.","DOI":"10.3390\/ijms252312990"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"315","DOI":"10.2471\/BLT.19.237149","article-title":"Herpes simplex virus: Global infection prevalence and incidence estimates, 2016","volume":"98","author":"James","year":"2020","journal-title":"Bull. World Health Organ."},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Scarsella, L., Ehrke-Schulz, E., Paulussen, M., Thal, S.C., Ehrhardt, A., and Aydin, M. (2024). Advances of Recombinant Adenoviral Vectors in Preclinical and Clinical Applications. Viruses, 16.","DOI":"10.3390\/v16030377"},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Tseha, S.T. (2022). Role of Adenoviruses in Cancer Therapy. Front. Oncol., 12.","DOI":"10.3389\/fonc.2022.772659"},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"Trivedi, P.D., Byrne, B.J., and Corti, M. (2023). Evolving Horizons: Adenovirus Vectors\u2019 Timeless Influence on Cancer, Gene Therapy and Vaccines. Viruses, 15.","DOI":"10.3390\/v15122378"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.virol.2005.09.037","article-title":"Poxvirus entry and membrane fusion","volume":"344","author":"Moss","year":"2006","journal-title":"Virology"},{"key":"ref_26","first-page":"646","article-title":"Preclinical and clinical trials of oncolytic vaccinia virus in cancer immunotherapy: A comprehensive review","volume":"20","author":"Li","year":"2023","journal-title":"Cancer Biol. Med."},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Xu, L., Sun, H., Lemoine, N.R., Xuan, Y., and Wang, P. (2023). Oncolytic vaccinia virus and cancer immunotherapy. Front. Immunol., 14.","DOI":"10.3389\/fimmu.2023.1324744"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1128\/jvi.64.3.1014-1020.1990","article-title":"The herpes simplex virus 1 gene for ICP34.5, which maps in inverted repeats, is conserved in several limited-passage isolates but not in strain 17syn+","volume":"64","author":"Chou","year":"1990","journal-title":"J. Virol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1128\/JVI.80.3.1110-1120.2006","article-title":"Activated MEK suppresses activation of PKR and enables efficient replication and in vivo oncolysis by Deltagamma(1)34.5 mutants of herpes simplex virus 1","volume":"80","author":"Smith","year":"2006","journal-title":"J. Virol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1073\/pnas.94.3.843","article-title":"The gamma(1)34.5 protein of herpes simplex virus 1 complexes with protein phosphatase 1alpha to dephosphorylate the alpha subunit of the eukaryotic translation initiation factor 2 and preclude the shutoff of protein synthesis by double-stranded RNA-activated protein kinase","volume":"94","author":"He","year":"1997","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"12128","DOI":"10.1128\/JVI.01356-07","article-title":"Analysis of the role of autophagy in replication of herpes simplex virus in cell culture","volume":"81","author":"Alexander","year":"2007","journal-title":"J. Virol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"e01015-18","DOI":"10.1128\/JVI.01015-18","article-title":"Herpes Simplex Virus 1 \u03b3(1)34.5 Protein Inhibits STING Activation That Restricts Viral Replication","volume":"92","author":"Pan","year":"2018","journal-title":"J. Virol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1038\/sj.gt.3301885","article-title":"ICP34.5 deleted herpes simplex virus with enhanced oncolytic, immune stimulating, and anti-tumour properties","volume":"10","author":"Liu","year":"2003","journal-title":"Gene Ther."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"4005","DOI":"10.1158\/1078-0432.CCR-10-0196","article-title":"Phase I\/II study of oncolytic HSV GM-CSF in combination with radiotherapy and cisplatin in untreated stage III\/IV squamous cell cancer of the head and neck","volume":"16","author":"Harrington","year":"2010","journal-title":"Clin. Cancer Res."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"5153","DOI":"10.1158\/1078-0432.CCR-20-1170","article-title":"Talimogene Laherparepvec and Pembrolizumab in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (MASTERKEY-232): A Multicenter, Phase 1b Study","volume":"26","author":"Harrington","year":"2020","journal-title":"Clin. Cancer Res."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"e011642","DOI":"10.1136\/jitc-2025-011642","article-title":"Preclinical and clinical evaluation of intratumoral injection of an IL-12 expressing SKV-012 oncolytic virus for advanced solid tumors","volume":"13","author":"Jiang","year":"2025","journal-title":"J. Immunother. Cancer"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"199639","DOI":"10.1016\/j.virusres.2025.199639","article-title":"Phase I clinical trial of a recombinant oncolytic virus injection combined with PD-1 antibody-based gene therapy for recurrent head and neck cancer in China: An open-label study","volume":"361","author":"Zhu","year":"2025","journal-title":"Virus Res."},{"key":"ref_38","doi-asserted-by":"crossref","unstructured":"Eissa, I.R., Naoe, Y., Bustos-Villalobos, I., Ichinose, T., Tanaka, M., Zhiwen, W., Mukoyama, N., Morimoto, T., Miyajima, N., and Hitoki, H. (2017). Genomic Signature of the Natural Oncolytic Herpes Simplex Virus HF10 and Its Therapeutic Role in Preclinical and Clinical Trials. Front. Oncol., 7.","DOI":"10.3389\/fonc.2017.00149"},{"key":"ref_39","doi-asserted-by":"crossref","unstructured":"Ji, D., Fu, W., Liu, Y., Shen, W., Kuang, M., Ning, Z., Sang, Y., Chen, G., Zhang, J., and Zhou, Z. (2026). First-in-human phase 1\/2a study of T3011, an oncolytic HSV expressing IL-12 and PD-1 antibody, administered via intratumoral (IT) injection as monotherapy in advanced solid tumors, including recurrent or metastatic HNSCC. BMC Med., 24.","DOI":"10.1186\/s12916-026-04695-1"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"e002224","DOI":"10.1136\/jitc-2020-002224","article-title":"Intratumoral OH2, an oncolytic herpes simplex virus 2, in patients with advanced solid tumors: A multicenter, phase I\/II clinical trial","volume":"9","author":"Zhang","year":"2021","journal-title":"J. Immunother. Cancer"},{"key":"ref_41","first-page":"6359","article-title":"Selective replication and oncolysis in p53 mutant tumors with ONYX-015, an E1B-55kD gene-deleted adenovirus, in patients with advanced head and neck cancer: A phase II trial","volume":"60","author":"Nemunaitis","year":"2000","journal-title":"Cancer Res."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"3715","DOI":"10.1158\/1078-0432.CCR-23-3874","article-title":"Safety, Efficacy, and Biological Data of T-Cell-Enabling Oncolytic Adenovirus TILT-123 in Advanced Solid Cancers from the TUNIMO Monotherapy Phase I Trial","volume":"30","author":"Pakola","year":"2024","journal-title":"Clin. Cancer Res."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"e006561","DOI":"10.1136\/jitc-2022-006561","article-title":"Safety and efficacy of the tumor-selective adenovirus enadenotucirev, in combination with nivolumab, in patients with advanced\/metastatic epithelial cancer: A phase I clinical trial (SPICE)","volume":"11","author":"Fakih","year":"2023","journal-title":"J. Immunother. Cancer"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"e010016","DOI":"10.1136\/jitc-2024-010016","article-title":"First-in-human clinical outcomes with NG-350A, an anti-CD40 expressing tumor-selective vector designed to remodel immunosuppressive tumor microenvironments","volume":"12","author":"Naing","year":"2024","journal-title":"J. Immunother. Cancer"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"5696","DOI":"10.1158\/1078-0432.CCR-16-3232","article-title":"Phase I Trial of Intravenous Oncolytic Vaccinia Virus (GL-ONC1) with Cisplatin and Radiotherapy in Patients with Locoregionally Advanced Head and Neck Carcinoma","volume":"23","author":"Mell","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1200\/JCO.2001.19.2.289","article-title":"Phase II trial of intratumoral administration of ONYX-015, a replication-selective adenovirus, in patients with refractory head and neck cancer","volume":"19","author":"Nemunaitis","year":"2001","journal-title":"J. Clin. Oncol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1038\/78638","article-title":"a controlled trial of intratumoral ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer","volume":"6","author":"Khuri","year":"2000","journal-title":"Nat. Med."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.omto.2016.12.004","article-title":"Oncolytic Adenoviruses Armed with Tumor Necrosis Factor Alpha and Interleukin-2 Enable Successful Adoptive Cell Therapy","volume":"4","author":"Havunen","year":"2017","journal-title":"Mol. Ther. Oncolytics"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"100726","DOI":"10.1016\/j.iotech.2024.100726","article-title":"Durable complete response after combined treatment with tumor-infiltrating lymphocytes and oncolytic adenovirus (TILT-123) in a patient with metastatic mucosal melanoma","volume":"24","author":"Monberg","year":"2024","journal-title":"Immuno-Oncol. Technol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.omto.2016.11.003","article-title":"Oncolytic Group B Adenovirus Enadenotucirev Mediates Non-apoptotic Cell Death with Membrane Disruption and Release of Inflammatory Mediators","volume":"4","author":"Dyer","year":"2017","journal-title":"Mol. Ther. Oncolytics"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.omto.2021.05.009","article-title":"Hyaluronidase expression within tumors increases virotherapy efficacy and T cell accumulation","volume":"22","author":"Moreno","year":"2021","journal-title":"Mol. Ther. Oncolytics"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1007\/s00438-009-0475-1","article-title":"The highly attenuated oncolytic recombinant vaccinia virus GLV-1h68: Comparative genomic features and the contribution of F14.5L inactivation","volume":"282","author":"Zhang","year":"2009","journal-title":"Mol. Genet. Genom."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.oraloncology.2012.07.019","article-title":"Oncolytic Vaccinia virus and radiotherapy in head and neck cancer","volume":"49","author":"Mansfield","year":"2013","journal-title":"Oral Oncol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"81208","DOI":"10.18632\/oncotarget.12820","article-title":"Oncolytic vaccinia virus combined with radiotherapy induces apoptotic cell death in sarcoma cells by down-regulating the inhibitors of apoptosis","volume":"7","author":"Wilkinson","year":"2016","journal-title":"Oncotarget"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"6737","DOI":"10.1158\/1078-0432.CCR-06-0759","article-title":"A phase I study of OncoVEXGM-CSF, a second-generation oncolytic herpes simplex virus expressing granulocyte macrophage colony-stimulating factor","volume":"12","author":"Hu","year":"2006","journal-title":"Clin. Cancer Res."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1186\/s40425-019-0623-z","article-title":"Final analyses of OPTiM: A randomized phase III trial of talimogene laherparepvec versus granulocyte-macrophage colony-stimulating factor in unresectable stage III-IV melanoma","volume":"7","author":"Andtbacka","year":"2019","journal-title":"J. Immunother. Cancer"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1200\/JCO.22.00343","article-title":"Randomized, Double-Blind, Placebo-Controlled, Global Phase III Trial of Talimogene Laherparepvec Combined with Pembrolizumab for Advanced Melanoma","volume":"41","author":"Chesney","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1038\/s41392-024-02029-2","article-title":"Neoadjuvant oncolytic virus orienx010 and toripalimab in resectable acral melanoma: A phase Ib trial","volume":"9","author":"Liu","year":"2024","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"e006270","DOI":"10.1136\/jitc-2022-006270","article-title":"Talimogene laherparepvec in combination with ipilimumab versus ipilimumab alone for advanced melanoma: 5-year final analysis of a multicenter, randomized, open-label, phase II trial","volume":"11","author":"Chesney","year":"2023","journal-title":"J. Immunother. Cancer"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1038\/nm0995-938","article-title":"Attenuated multi-mutated herpes simplex virus-1 for the treatment of malignant gliomas","volume":"1","author":"Mineta","year":"1995","journal-title":"Nat. Med."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1038\/mt.2014.22","article-title":"A phase 1 trial of oncolytic HSV-1, G207, given in combination with radiation for recurrent GBM demonstrates safety and radiographic responses","volume":"22","author":"Markert","year":"2014","journal-title":"Mol. Ther."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.1056\/NEJMoa2024947","article-title":"Oncolytic HSV-1 G207 Immunovirotherapy for Pediatric High-Grade Gliomas","volume":"384","author":"Friedman","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1038\/s41591-022-01897-x","article-title":"Intratumoral oncolytic herpes virus G47\u2206 for residual or recurrent glioblastoma: A phase 2 trial","volume":"28","author":"Todo","year":"2022","journal-title":"Nat. Med."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"2832","DOI":"10.1158\/0008-5472.CAN-04-3227","article-title":"An oncolytic HSV-1 mutant expressing ICP34.5 under control of a nestin promoter increases survival of animals even when symptomatic from a brain tumor","volume":"65","author":"Kambara","year":"2005","journal-title":"Cancer Res."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1038\/s41586-023-06623-2","article-title":"Clinical trial links oncolytic immunoactivation to survival in glioblastoma","volume":"623","author":"Ling","year":"2023","journal-title":"Nature"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"100884","DOI":"10.1016\/j.esmoop.2023.100884","article-title":"Phase Ib study of talimogene laherparepvec in combination with atezolizumab in patients with triple negative breast cancer and colorectal cancer with liver metastases","volume":"8","author":"Hecht","year":"2023","journal-title":"ESMO Open"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1517\/13543784.17.7.1105","article-title":"Herpes simplex virus NV1020 as a novel and promising therapy for hepatic malignancy","volume":"17","author":"Kelly","year":"2008","journal-title":"Expert Opin. Investig. Drugs"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"e008025","DOI":"10.1136\/jitc-2023-008025","article-title":"Cytokine-armed oncolytic herpes simplex viruses: A game-changer in cancer immunotherapy?","volume":"12","author":"Wang","year":"2024","journal-title":"J. Immunother. Cancer"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1089\/hum.2010.020","article-title":"Phase I\/II study of oncolytic herpes simplex virus NV1020 in patients with extensively pretreated refractory colorectal cancer metastatic to the liver","volume":"21","author":"Geevarghese","year":"2010","journal-title":"Hum. Gene Ther."},{"key":"ref_70","doi-asserted-by":"crossref","unstructured":"Chawla, S.P., Tellez, W.A., Chomoyan, H., Valencia, C., Ahari, A., Omelchenko, N., Makrievski, S., Brigham, D.A., Chua-Alcala, V., and Quon, D. (2023). Activity of TNT: A phase 2 study using talimogene laherparepvec, nivolumab and trabectedin for previously treated patients with advanced sarcomas (NCT# 03886311). Front. Oncol., 13.","DOI":"10.3389\/fonc.2023.1116937"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1001\/jamaoncol.2019.6152","article-title":"Objective Response Rate Among Patients with Locally Advanced or Metastatic Sarcoma Treated with Talimogene Laherparepvec in Combination with Pembrolizumab: A Phase 2 Clinical Trial","volume":"6","author":"Kelly","year":"2020","journal-title":"JAMA Oncol."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.ejca.2021.04.043","article-title":"Phase I dose-escalation study of endoscopic intratumoral injection of OBP-301 (Telomelysin) with radiotherapy in oesophageal cancer patients unfit for standard treatments","volume":"153","author":"Shirakawa","year":"2021","journal-title":"Eur. J. Cancer"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1186\/s13046-024-03219-0","article-title":"Single intravenous administration of oncolytic adenovirus TILT-123 results in systemic tumor transduction and immune response in patients with advanced solid tumors","volume":"43","author":"Jirovec","year":"2024","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"102016","DOI":"10.1016\/j.xcrm.2025.102016","article-title":"Safety and efficacy of combined treatment with tumor-infiltrating lymphocytes and oncolytic adenovirus TILT-123 in metastatic melanoma","volume":"6","author":"Monberg","year":"2025","journal-title":"Cell Rep. Med."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"e003645","DOI":"10.1136\/jitc-2021-003645","article-title":"Safety and efficacy of the tumor-selective adenovirus enadenotucirev with or without paclitaxel in platinum-resistant ovarian cancer: A phase 1 clinical trial","volume":"9","author":"Moreno","year":"2021","journal-title":"J. Immunother. Cancer"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1038\/s41591-023-02347-y","article-title":"Oncolytic DNX-2401 virotherapy plus pembrolizumab in recurrent glioblastoma: A phase 1\/2 trial","volume":"29","author":"Nassiri","year":"2023","journal-title":"Nat. Med."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"9299","DOI":"10.1038\/s41467-024-53041-7","article-title":"Non-secreting IL12 expressing oncolytic adenovirus Ad-TD-nsIL12 in recurrent high-grade glioma: A phase I trial","volume":"15","author":"Ning","year":"2024","journal-title":"Nat. Commun."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1016\/j.ygyno.2021.10.069","article-title":"A phase 1b study of intraperitoneal oncolytic viral immunotherapy in platinum-resistant or refractory ovarian cancer","volume":"163","author":"Manyam","year":"2021","journal-title":"Gynecol. Oncol."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1038\/mt.2015.109","article-title":"Phase 1b Trial of Biweekly Intravenous Pexa-Vec (JX-594), an Oncolytic and Immunotherapeutic Vaccinia Virus in Colorectal Cancer","volume":"23","author":"Park","year":"2015","journal-title":"Mol. Ther."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"e005640","DOI":"10.1136\/jitc-2022-005640","article-title":"Phase I\/II study of PexaVec in combination with immune checkpoint inhibition in refractory metastatic colorectal cancer","volume":"11","author":"Monge","year":"2023","journal-title":"J. Immunother. Cancer"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1186\/s12943-024-01946-8","article-title":"Reshaping the tumor microenvironment of cold soft-tissue sarcomas with oncolytic viral therapy: A phase 2 trial of intratumoral JX-594 combined with avelumab and low-dose cyclophosphamide","volume":"23","author":"Toulmonde","year":"2024","journal-title":"Mol. Cancer"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1158\/1078-0432.CCR-24-2498","article-title":"A Phase I Clinical Trial of Intrahepatic Artery Delivery of TG6002 in Combination with Oral 5-Fluorocytosine in Patients with Liver-Dominant Metastatic Colorectal Cancer","volume":"31","author":"West","year":"2025","journal-title":"Clin. Cancer Res."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"3635","DOI":"10.1158\/0008-5472.CAN-21-0035","article-title":"An Oncolytic Virus Expressing IL15\/IL15R\u03b1 Combined with Off-the-Shelf EGFR-CAR NK Cells Targets Glioblastoma","volume":"81","author":"Ma","year":"2021","journal-title":"Cancer Res."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"23671","DOI":"10.1038\/s41598-024-72888-w","article-title":"Improved antitumor effectiveness of oncolytic HSV-1 viruses engineered with IL-15\/IL-15R\u03b1 complex combined with oncolytic HSV-1-aPD1 targets colon cancer","volume":"14","author":"Hu","year":"2024","journal-title":"Sci. Rep."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"4016","DOI":"10.7150\/thno.83495","article-title":"OX40L-Armed Oncolytic Virus Boosts T-cell Response and Remodels Tumor Microenvironment for Pancreatic Cancer Treatment","volume":"13","author":"Liu","year":"2023","journal-title":"Theranostics"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"200784","DOI":"10.1016\/j.omton.2024.200784","article-title":"TheraVision: Engineering platform technology for the development of oncolytic viruses based on herpes simplex virus type 1","volume":"32","author":"Funk","year":"2024","journal-title":"Mol. Ther. Oncol."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"201132","DOI":"10.1016\/j.omton.2026.201132","article-title":"Strategically engineering an oncolytic herpes simplex virus to improve systemic delivery","volume":"34","author":"Fu","year":"2026","journal-title":"Mol. Ther. Oncol."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1186\/s12985-022-01795-1","article-title":"A novel cocktail therapy based on quintuplet combination of oncolytic herpes simplex virus-2 vectors armed with interleukin-12, interleukin-15, GM-CSF, PD1v, and IL-7\u2009\u00d7\u2009CCL19 results in enhanced antitumor efficacy","volume":"19","author":"Hu","year":"2022","journal-title":"Virol. J."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"e003000","DOI":"10.1136\/jitc-2021-003000","article-title":"Novel oncolytic adenovirus expressing enhanced cross-hybrid IgGA Fc PD-L1 inhibitor activates multiple immune effector populations leading to enhanced tumor killing in vitro, in vivo and with patient-derived tumor organoids","volume":"9","author":"Hamdan","year":"2021","journal-title":"J. Immunother. Cancer"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1038\/gt.2011.176","article-title":"Targeted cancer immunotherapy with oncolytic adenovirus coding for a fully human monoclonal antibody specific for CTLA-4","volume":"19","author":"Dias","year":"2012","journal-title":"Gene Ther."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"106701","DOI":"10.1016\/j.phrs.2023.106701","article-title":"Oncolytic adenovirus-mediated expression of CCL5 and IL12 facilitates CA9-targeting CAR-T therapy against renal cell carcinoma","volume":"189","author":"Fang","year":"2023","journal-title":"Pharmacol. Res."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.ymthe.2022.08.021","article-title":"CXCL11-armed oncolytic adenoviruses enhance CAR-T cell therapeutic efficacy and reprogram tumor microenvironment in glioblastoma","volume":"31","author":"Wang","year":"2023","journal-title":"Mol. Ther."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.trsl.2024.07.002","article-title":"An optimal promoter regulating cytokine transgene expression is crucial for safe and effective oncolytic virus immunotherapy","volume":"273","author":"Kawakami","year":"2024","journal-title":"Transl. Res."},{"key":"ref_94","doi-asserted-by":"crossref","unstructured":"Yang, Q., Shu, Y., Chen, Y., Qi, Z., Hu, S., Zhang, Y., Qin, Y., Xu, X., Hu, J., and Huang, A. (2025). Expression of SIRP\u03b1-Fc by oncolytic virus enhances antitumor efficacy through tumor microenvironment reprogramming. Front. Immunol., 16.","DOI":"10.3389\/fimmu.2025.1513555"},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"6872","DOI":"10.1158\/0008-5472.CAN-06-3244","article-title":"Targeted cancer gene therapy using a hypoxia inducible factor dependent oncolytic adenovirus armed with interleukin-4","volume":"67","author":"Post","year":"2007","journal-title":"Cancer Res."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1038\/s41467-020-15229-5","article-title":"An engineered oncolytic virus expressing PD-L1 inhibitors activates tumor neoantigen-specific T cell responses","volume":"11","author":"Wang","year":"2020","journal-title":"Nat. Commun."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"103240","DOI":"10.1016\/j.ebiom.2021.103240","article-title":"Enhanced antitumor efficacy of a novel oncolytic vaccinia virus encoding a fully monoclonal antibody against T-cell immunoglobulin and ITIM domain (TIGIT)","volume":"64","author":"Zuo","year":"2021","journal-title":"eBioMedicine"},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.omto.2017.12.002","article-title":"Development of a Safe and Effective Vaccinia Virus Oncolytic Vector WR-\u03944 with a Set of Gene Deletions on Several Viral Pathways","volume":"8","author":"Esteban","year":"2018","journal-title":"Mol. Ther. Oncolytics"},{"key":"ref_99","doi-asserted-by":"crossref","unstructured":"Zha, M., Huang, F., Li, S., Wang, Q., and Tang, Y. (2025). Advances of oncolytic vaccinia viruses armed with interleukin in tumor therapy. Front. Oncol., 15.","DOI":"10.3389\/fonc.2025.1594621"},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"e1395997","DOI":"10.1080\/2162402X.2017.1395997","article-title":"Intra-tumoral delivery of CXCL11 via a vaccinia virus, but not by modified T cells, enhances the efficacy of adoptive T cell therapy and vaccines","volume":"7","author":"Moon","year":"2018","journal-title":"Oncoimmunology"},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"e006024","DOI":"10.1136\/jitc-2022-006024","article-title":"Generation of novel oncolytic vaccinia virus with improved intravenous efficacy through protection against complement-mediated lysis and evasion of neutralization by vaccinia virus-specific antibodies","volume":"11","author":"Lee","year":"2023","journal-title":"J. Immunother. Cancer"},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/j.omtm.2020.01.001","article-title":"Oncolytic Viruses and the Immune System: The Dynamic Duo","volume":"17","author":"Franco","year":"2020","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"ref_103","doi-asserted-by":"crossref","unstructured":"Tang, G., Wang, D., Zhao, X., Feng, Z., Chen, Q., and Shen, Y. (2023). The Dilemma of HSV-1 Oncolytic Virus Delivery: The Method Choice and Hurdles. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms24043681"},{"key":"ref_104","first-page":"830","article-title":"Progress in oncolytic viruses modified with nanomaterials for intravenous application","volume":"20","author":"Chen","year":"2023","journal-title":"Cancer Biol. Med."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1038\/s41417-022-00469-y","article-title":"Challenges and progress toward tumor-targeted therapy by systemic delivery of polymer-complexed oncolytic adenoviruses","volume":"29","author":"Thambi","year":"2022","journal-title":"Cancer Gene Ther."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"e3177","DOI":"10.1002\/jgm.3177","article-title":"Folate-conjugated herpes simplex virus for retargeting to tumor cells","volume":"22","author":"Ye","year":"2020","journal-title":"J. Gene Med."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"5452","DOI":"10.7150\/thno.87498","article-title":"Systemic delivery of glycosylated-PEG-masked oncolytic virus enhances targeting of antitumor immuno-virotherapy and modulates T and NK cell infiltration","volume":"13","author":"Liang","year":"2023","journal-title":"Theranostics"},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"172991","DOI":"10.1016\/j.ejphar.2020.172991","article-title":"Mesenchymal stem cells as carriers for systemic delivery of oncolytic viruses","volume":"874","author":"Sochanik","year":"2020","journal-title":"Eur. J. Pharmacol."},{"key":"ref_109","doi-asserted-by":"crossref","unstructured":"Reale, A., Calistri, A., and Altomonte, J. (2021). Giving Oncolytic Viruses a Free Ride: Carrier Cells for Oncolytic Virotherapy. Pharmaceutics, 13.","DOI":"10.3390\/pharmaceutics13122192"},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"200788","DOI":"10.1016\/j.omton.2024.200788","article-title":"Advances in cell-based delivery of oncolytic viruses as therapy for lung cancer","volume":"32","author":"Nia","year":"2024","journal-title":"Mol. Ther. Oncol."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"E6157","DOI":"10.1073\/pnas.1700363114","article-title":"Stem cell-released oncolytic herpes simplex virus has therapeutic efficacy in brain metastatic melanomas","volume":"114","author":"Du","year":"2017","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1038\/cgt.2011.91","article-title":"Antitumor efficacy of oncolytic herpes simplex virus adsorbed onto antigen-specific lymphocytes","volume":"19","author":"Kanzaki","year":"2012","journal-title":"Cancer Gene Ther."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1007\/s00262-024-03757-8","article-title":"Systemic delivery of oncolytic herpes virus using CAR-T cells enhances targeting of antitumor immuno-virotherapy","volume":"73","author":"Zhang","year":"2024","journal-title":"Cancer Immunol. Immunother."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1016\/j.ymthe.2020.01.019","article-title":"First-in-Human, First-in-Child Trial of Autologous MSCs Carrying the Oncolytic Virus Icovir-5 in Patients with Advanced Tumors","volume":"28","author":"Ruano","year":"2020","journal-title":"Mol. Ther."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1038\/s41571-021-00507-y","article-title":"Intratumoural administration and tumour tissue targeting of cancer immunotherapies","volume":"18","author":"Melero","year":"2021","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1186\/s40644-024-00763-y","article-title":"Ultrasound-guided intra-tumoral administration of directly-injected therapies: A review of the technical and logistical considerations","volume":"24","author":"Bitar","year":"2024","journal-title":"Cancer Imaging"},{"key":"ref_117","doi-asserted-by":"crossref","unstructured":"Said, A., Hoang, H.D., Earl, N., Xiang, X., Siddiqui, N., C\u00f4t\u00e9, M., and Alain, T. (2023). High-Pressure Delivery of Oncolytic Viruses via Needle-Free Injection Preserves Therapeutic Activity. Cancers, 15.","DOI":"10.3390\/cancers15235655"},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1186\/s12951-024-02903-9","article-title":"Novel combination therapy using recombinant oncolytic adenovirus silk hydrogel and PD-L1 inhibitor for bladder cancer treatment","volume":"22","author":"Zhang","year":"2024","journal-title":"J. Nanobiotechnol."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1038\/s42003-023-04983-z","article-title":"Navoximod modulates local HSV-1 replication to reshape tumor immune microenvironment for enhanced immunotherapy via an injectable hydrogel","volume":"6","author":"Zhuang","year":"2023","journal-title":"Commun. Biol."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1016\/j.ultrasmedbio.2007.12.015","article-title":"Effect of focused ultrasound applied with an ultrasound contrast agent on the tight junctional integrity of the brain microvascular endothelium","volume":"34","author":"Sheikov","year":"2008","journal-title":"Ultrasound Med. Biol."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.jconrel.2011.09.068","article-title":"Controlled permeation of cell membrane by single bubble acoustic cavitation","volume":"157","author":"Zhou","year":"2012","journal-title":"J. Control. Release"},{"key":"ref_122","doi-asserted-by":"crossref","unstructured":"Yura, Y., Fujita, Y., and Hamada, M. (2024). Ultrasound Combination to Improve the Efficacy of Current Boron Neutron Capture Therapy for Head and Neck Cancer. Cancers, 16.","DOI":"10.3390\/cancers16152770"},{"key":"ref_123","first-page":"193","article-title":"Ultrasound-mediated oncolytic virus delivery and uptake for increased therapeutic efficacy: State of art","volume":"4","author":"Nande","year":"2015","journal-title":"Oncolytic Virother."},{"key":"ref_124","doi-asserted-by":"crossref","unstructured":"Hoshi, R., Gorospe, K.A., Labouta, H.I., Azad, T., Lee, W.L., and Thu, K.L. (2024). Alternative Strategies for Delivering Immunotherapeutics Targeting the PD-1\/PD-L1 Immune Checkpoint in Cancer. Pharmaceutics, 16.","DOI":"10.3390\/pharmaceutics16091181"},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1016\/S1470-2045(18)30332-2","article-title":"Safety and feasibility of ultrasound-triggered targeted drug delivery of doxorubicin from thermosensitive liposomes in liver tumours (TARDOX): A single-centre, open-label, phase 1 trial","volume":"19","author":"Lyon","year":"2018","journal-title":"Lancet Oncol."},{"key":"ref_126","doi-asserted-by":"crossref","unstructured":"Sitta, J., De Carlo, F., Kirven, I., Tackett, J.H., Penfornis, P., Dobbins, G.C., Barbier, M., Del Valle, L., Larsen, C.T., and Schutt, E.G. (2024). Microbubble-Protected Oncolytic Virotherapy Targeted by Sonoporation Induces Tumor Necrosis and T-Lymphocyte Infiltration in Humanized Mice Bearing Triple-Negative Breast Cancer. Int. J. Mol. Sci., 25.","DOI":"10.3390\/ijms252413697"},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1038\/mt.2009.252","article-title":"Eradication of therapy-resistant human prostate tumors using an ultrasound-guided site-specific cancer terminator virus delivery approach","volume":"18","author":"Greco","year":"2010","journal-title":"Mol. Ther."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1186\/1743-422X-8-446","article-title":"Effect of ultrasound on herpes simplex virus infection in cell culture","volume":"8","author":"Shintani","year":"2011","journal-title":"Virol. J."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1038\/cgt.2015.3","article-title":"Ultrasound as a method to enhance antitumor ability of oncolytic herpes simplex virus for head and neck cancer","volume":"22","author":"Okunaga","year":"2015","journal-title":"Cancer Gene Ther."},{"key":"ref_130","doi-asserted-by":"crossref","unstructured":"Marino-Merlo, F., Papaianni, E., Frezza, C., Pedatella, S., De Nisco, M., Macchi, B., Grelli, S., and Mastino, A. (2019). NF-\u03baB-Dependent Production of ROS and Restriction of HSV-1 Infection in U937 Monocytic Cells. Viruses, 11.","DOI":"10.3390\/v11050428"},{"key":"ref_131","doi-asserted-by":"crossref","unstructured":"Marchini, A., Scott, E.M., and Rommelaere, J. (2016). Overcoming Barriers in Oncolytic Virotherapy with HDAC Inhibitors and Immune Checkpoint Blockade. Viruses, 8.","DOI":"10.3390\/v8010009"},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1038\/mt.2012.265","article-title":"HDAC inhibition suppresses primary immune responses, enhances secondary immune responses, and abrogates autoimmunity during tumor immunotherapy","volume":"21","author":"Bridle","year":"2013","journal-title":"Mol. Ther."},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1016\/j.ymthe.2019.04.008","article-title":"Potentiating Oncolytic Virus-Induced Immune-Mediated Tumor Cell Killing Using Histone Deacetylase Inhibition","volume":"27","author":"Jennings","year":"2019","journal-title":"Mol. Ther."},{"key":"ref_134","doi-asserted-by":"crossref","unstructured":"MacTavish, H., Diallo, J.S., Huang, B., Stanford, M., Le Boeuf, F., De Silva, N., Cox, J., Simmons, J.G., Guimond, T., and Falls, T. (2010). Enhancement of vaccinia virus based oncolysis with histone deacetylase inhibitors. PLoS ONE, 5.","DOI":"10.1371\/journal.pone.0014462"},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1038\/cgt.2008.81","article-title":"The effects of trichostatin A on the oncolytic ability of herpes simplex virus for oral squamous cell carcinoma cells","volume":"16","author":"Katsura","year":"2009","journal-title":"Cancer Gene Ther."},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1111\/cas.16032","article-title":"Histone deacetylase inhibitor boosts anticancer potential of fusogenic oncolytic vaccinia virus by enhancing cell-cell fusion","volume":"115","author":"Nakatake","year":"2024","journal-title":"Cancer Sci."},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1038\/cgt.2012.57","article-title":"Enhanced antitumor efficacy of telomerase-specific oncolytic adenovirus with valproic acid against human cancer cells","volume":"19","author":"Watanabe","year":"2012","journal-title":"Cancer Gene Ther."},{"key":"ref_138","doi-asserted-by":"crossref","unstructured":"Alwithenani, A., Taha, Z., Thomson, M., Chen, A., Wong, B., Arulanandam, R., and Diallo, J.S. (2023). Unlocking the potential of dimethyl fumarate: Enhancing oncolytic HSV-1 efficacy for wider cancer applications. Front. Immunol., 14.","DOI":"10.3389\/fimmu.2023.1332929"},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"200ra116","DOI":"10.1126\/scitranslmed.3006504","article-title":"Up-regulation of PD-L1, IDO, and T(regs) in the melanoma tumor microenvironment is driven by CD8(+) T cells","volume":"5","author":"Spranger","year":"2013","journal-title":"Sci. Transl. Med."},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"48","DOI":"10.4161\/cbt.5.1.2237","article-title":"Cisplatin-induced GADD34 upregulation potentiates oncolytic viral therapy in the treatment of malignant pleural mesothelioma","volume":"5","author":"Adusumilli","year":"2006","journal-title":"Cancer Biol. Ther."},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1002\/ijc.25808","article-title":"Rapamycin enhances the activity of oncolytic herpes simplex virus against tumor cells that are resistant to virus replication","volume":"129","author":"Fu","year":"2011","journal-title":"Int. J. Cancer"},{"key":"ref_142","doi-asserted-by":"crossref","unstructured":"Aboaid, H., Khalid, T., Hussain, A., Myat, Y.M., Nanda, R.K., Srinivasmurthy, R., Nguyen, K., Jones, D.T., Bigcas, J.L., and Thein, K.Z. (2025). Advances and challenges in immunotherapy in head and neck cancer. Front. Immunol., 16.","DOI":"10.3389\/fimmu.2025.1596583"},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"1676","DOI":"10.1158\/0008-5472.CAN-12-2448","article-title":"Phase I trial of recombinant modified vaccinia ankara encoding Epstein-Barr viral tumor antigens in nasopharyngeal carcinoma patients","volume":"73","author":"Hui","year":"2013","journal-title":"Cancer Res."},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"5009","DOI":"10.1158\/1078-0432.CCR-14-1122-T","article-title":"A recombinant modified vaccinia ankara vaccine encoding Epstein-Barr Virus (EBV) target antigens: A phase I trial in UK patients with EBV-positive cancer","volume":"20","author":"Taylor","year":"2014","journal-title":"Clin. Cancer Res."},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/s40661-017-0047-8","article-title":"Therapeutic options for treatment of human papillomavirus-associated cancers\u2014Novel immunologic vaccines: ADXS11-001","volume":"4","author":"Miles","year":"2017","journal-title":"Gynecol. Oncol. Res. Pr."},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1111\/cas.14784","article-title":"Personalized cancer vaccination in head and neck cancer","volume":"112","author":"Shibata","year":"2021","journal-title":"Cancer Sci."},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"189138","DOI":"10.1016\/j.bbcan.2024.189138","article-title":"Immunotherapy for HPV negative head and neck squamous cell carcinoma","volume":"1879","author":"Jiang","year":"2024","journal-title":"Biochim. Biophys. Acta Rev. Cancer"},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1093\/annonc\/mds523","article-title":"A phase I dose escalation study of Ad GV.EGR.TNF.11D (TNFerade\u2122 Biologic) with concurrent chemoradiotherapy in patients with recurrent head and neck cancer undergoing reirradiation","volume":"24","author":"Seiwert","year":"2013","journal-title":"Ann. Oncol."},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1038\/mt.2014.53","article-title":"Multicenter randomized phase 2 clinical trial of a recombinant human endostatin adenovirus in patients with advanced head and neck carcinoma","volume":"22","author":"Ye","year":"2014","journal-title":"Mol. Ther."},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1093\/annonc\/mdr341","article-title":"A phase II study evaluating the safety and efficacy of an adenovirus-\u0394LMP1-LMP2 transduced dendritic cell vaccine in patients with advanced metastatic nasopharyngeal carcinoma","volume":"23","author":"Chia","year":"2012","journal-title":"Ann. Oncol."},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"oyaf006","DOI":"10.1093\/oncolo\/oyaf006","article-title":"Tri-Ad5 vaccine plus bintrafusp alfa for newly diagnosed, advanced-stage head and neck cancer not associated with human papillomavirus infection","volume":"30","author":"Redman","year":"2025","journal-title":"Oncologist"},{"key":"ref_152","doi-asserted-by":"crossref","unstructured":"Orlova, O.V., Glazkova, D.V., Bogoslovskaya, E.V., Shipulin, G.A., and Yudin, S.M. (2022). Development of Modified Vaccinia Virus Ankara-Based Vaccines: Advantages and Applications. Vaccines, 10.","DOI":"10.3390\/vaccines10091516"},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"a001008","DOI":"10.1101\/cshperspect.a001008","article-title":"TP53 mutations in human cancers: Origins, consequences, and clinical use","volume":"2","author":"Olivier","year":"2010","journal-title":"Cold Spring Harb. Perspect. Biol."},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1007\/s12094-018-1932-2","article-title":"Evaluation of safety and efficacy of p53MVA vaccine combined with pembrolizumab in patients with advanced solid cancers","volume":"21","author":"Chung","year":"2019","journal-title":"Clin. Transl. Oncol."},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/S1470-2045(15)00483-0","article-title":"TG4010 immunotherapy and first-line chemotherapy for advanced non-small-cell lung cancer (TIME): Results from the phase 2b part of a randomised, double-blind, placebo-controlled, phase 2b\/3 trial","volume":"17","author":"Quoix","year":"2016","journal-title":"Lancet Oncol."},{"key":"ref_156","doi-asserted-by":"crossref","first-page":"6016","DOI":"10.1200\/JCO.2025.43.16_suppl.6016","article-title":"Randomized phase I trial of adjuvant personalized cancer vaccine TG4050 in resected locally advanced (LA) head and neck squamous cell carcinoma (HNSCC) patients (pts)","volume":"43","author":"Tourneau","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"ref_157","doi-asserted-by":"crossref","unstructured":"Ding, J., Murad, Y.M., Sun, Y., Lee, I.F., Samudio, I., Liu, X., Jia, W.W., and Zhao, R. (2022). Pre-Existing HSV-1 Immunity Enhances Anticancer Efficacy of a Novel Immune-Stimulating Oncolytic Virus. Viruses, 14.","DOI":"10.3390\/v14112327"},{"key":"ref_158","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.cytogfr.2023.01.002","article-title":"Preexisting immunity: Barrier or bridge to effective oncolytic virus therapy?","volume":"70","author":"Groeneveldt","year":"2023","journal-title":"Cytokine Growth Factor Rev."},{"key":"ref_159","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1038\/sj.cgt.7700539","article-title":"Intravascular adenoviral agents in cancer patients: Lessons from clinical trials","volume":"9","author":"Reid","year":"2002","journal-title":"Cancer Gene Ther."},{"key":"ref_160","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1089\/hum.2006.17.1214","article-title":"Phase I, open-label, dose-escalating study of a genetically engineered herpes simplex virus, NV1020, in subjects with metastatic colorectal carcinoma to the liver","volume":"17","author":"Kemeny","year":"2006","journal-title":"Hum. Gene Ther."},{"key":"ref_161","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1007\/s10147-025-02702-8","article-title":"Dose-finding and efficacy confirmation trial of the superselective intra-arterial infusion of cisplatin and concomitant radiation therapy for locally advanced maxillary sinus cancer (JCOG1212): Final analysis","volume":"30","author":"Shinomiya","year":"2025","journal-title":"Int. J. Clin. Oncol."},{"key":"ref_162","first-page":"1917","article-title":"Superselective continuous arterial infusion chemotherapy through the superficial temporal artery for oral cavity tumors","volume":"21","author":"Nakasato","year":"2000","journal-title":"AJNR Am. J. Neuroradiol."},{"key":"ref_163","doi-asserted-by":"crossref","first-page":"E126","DOI":"10.1002\/hed.28205","article-title":"Superficial Temporal Artery-Based ReMAP: A Case Report Series in Head and Neck Cancer Intra-Arterial Chemotherapy","volume":"47","author":"Makino","year":"2025","journal-title":"Head Neck"},{"key":"ref_164","doi-asserted-by":"crossref","unstructured":"Li, Y., Li, L.J., Wang, L.J., Zhang, Z., Gao, N., Liang, C.Y., Huang, Y.D., and Han, B. (2014). Selective intra-arterial infusion of rAd-p53 with chemotherapy for advanced oral cancer: A randomized clinical trial. BMC Med., 12.","DOI":"10.1186\/1741-7015-12-16"},{"key":"ref_165","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1186\/s40425-017-0277-7","article-title":"Phase 1 study of intravenous administration of the chimeric adenovirus enadenotucirev in patients undergoing primary tumor resection","volume":"5","author":"Salazar","year":"2017","journal-title":"J. Immunother. Cancer"},{"key":"ref_166","doi-asserted-by":"crossref","unstructured":"Ferdous, K.U., Tesfay, M.Z., Cios, A., Shelton, R.S., Hartupee, C., Urbaniak, A., Chamcheu, J.C., Mavros, M.N., Giorgakis, E., and Mustafa, B. (2024). Enhancing Neoadjuvant Virotherapy\u2019s Effectiveness by Targeting Stroma to Improve Resectability in Pancreatic Cancer. Biomedicines, 12.","DOI":"10.3390\/biomedicines12071596"}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/27\/15\/6682\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T09:57:01Z","timestamp":1785146221000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/27\/15\/6682"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,27]]},"references-count":166,"journal-issue":{"issue":"15","published-online":{"date-parts":[[2026,8]]}},"alternative-id":["ijms27156682"],"URL":"https:\/\/doi.org\/10.3390\/ijms27156682","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,27]]}}}